EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

November 15, 2022

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 71 min

Earnings Call Speaker Segments

Nicola Fiore

unknown
#1

All right, good afternoon, everyone, and thanks for joining El.En.'s conference call covering the financial results for the third quarter of 2022. This call is being recorded, and it will also include a chance to ask questions near the end. Joining me are Andrea Cangioli, El.En.'s Managing Director, and Enrico Romagnoli, El.En.'s Chief Financial Officer and Investor Relations. Before we start, please be aware that management will make a remark on this call regarding future expectations, plans and prospects, and forward-looking statements. Some statements on this call — including those dealing with the company's beliefs, plans, objectives, estimates, or expectation of possible future results or events — are forward-looking statements. Forward-looking statements carry known or unknown risks, among them general economic and business conditions and conditions in the industry where the company operates, and they may be affected if the assumption proves inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance, or achievement could differ materially from those expressed or implied by such forward-looking statements. The company assumes no obligation regarding the contents, nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof. At this point, I'd like to hand the call over to Andrea Cangioli.

Nicola Fiore

unknown
#2

Andrea, please go ahead.

Andrea Cangioli

executive
#3

Thanks so much, Nicola, and thank you too, Bianca. I appreciate all of you for being on this call after we released our financial report for the end of the third quarter of 2022. Enrico Romagnoli is here with me on the call. After my introduction, where I'll give you a few comments on the very basic financial highlights and on the general trends of our businesses and of our performance, Enrico will walk you through the detailed specifics of our financial performance. Once again, the group turned in an outstanding performance, further speeding up the very fast growth trend from the first half of the year. With EUR 157 million in quarterly revenues, up 19.8% on 2021, bringing nine months total revenues to EUR 484 million, up 19.5% on 2021. On profitability, the financial showed strength with the sales volume increase, letting the EBIT margin hold the 12% record level on the nine months. After the third quarter, seasonally one of the weakest, and that was weaker than average in this 2022 as well, marking a 10.4% EBIT margin. The reason for such softer profitability in the quarter was, though, not limited to the summer slowdown only, but also and mainly to other reason I will examine right away.

Andrea Cangioli

executive
#4

Demand remained robust, and the strong performance was fairly broad across all application segments. Even with the substantial capacity increase we implemented, our order backlogs remain above the historical average—both in absolute value and in days of production. As you know, capacity expansion investments have been one of the group strategy's key pillars, and it's a great satisfaction for the company's management to see this multi-year effort progressively delivering the results of the infrastructure, R&D, and commercial long-term planning. Truly, there is great satisfaction regarding what we have achieved in this year to date: solid growth in revenues and profit, but most importantly, a solid and diversified organization that is proving able to respond to demand needs and seize the opportunities our end markets are providing to us. We are beating expectations and are still, and again, working on the foundation of our construction to make it even stronger. I want to share this with you before I begin to comment on a few gray spots that are showing up in the brilliant picture of our performance. In this successful year, there is, though, one area that is quite significant for our business, where the market response was not positive in the quarter and in the year.

Andrea Cangioli

executive
#5

When I talk about our China operations in the industrial sector, I mean our brand new manufacturing sites dedicated to large volume manufacturing of high-powered laser sheet metal cutting systems. China's situation is still being hampered by their unique approach to COVID, which keeps locking down entire regions in order to prevent the widespread of the disease, also by very limited number of positive individuals. It is well known that this policy led China, and is leading China, to isolation from the rest of the world, and also is internally creating many obstacles to the normal development of the mainland business activities. We firmly believe in the mid and long-term potential of Mainland China market, and we are continuing to invest in order to reinforce our local structure. We strongly believe that our products that on the same application markets are encountering an extraordinary success are going to lead once again to positive results as soon as the Chinese economy will start performing decently. Under this point of view, we welcome the news on the lighter limitation enforced on visitors entering China in terms of quarantine period, and also the apparently positive outcome of the Biden-Xi meeting. For our part, we are continuing to work on the project of a possible IPO of the business units on a Mainland China market, and we moved another step by allowing a couple of private equity firms to be part of the shareholder base of Penta Laser Zhejiang.

Andrea Cangioli

executive
#6

There's also one more condition — I'd call it a soft one — tied to the potential IPO. That IPO, as I remember it, would give the business unit a strong financial and structural boost, letting it design its rapid-growth strategies with more freedom, while El.En. would reduce the considerable financial weight of backing such very fast growth. This kind of development path has served us well in the past. Japan was another area where revenue fell in 2022. Regarding our subsidiary focused on the professional aesthetics business: the bad news is that revenue is down and the company posted a loss over the nine months. The good news is that breakeven was reached again in the third quarter. Also good news: the revenue we're missing is mostly low-margin revenue produced locally through our channels from sales of small home-use devices that complement the work done in beauty salons. The sharp sales increase in the aesthetic segment for the group that Enrico will show you shortly is net of this negative impact, and is therefore even higher if we count only the units we manufacture with our own technology.

Andrea Cangioli

executive
#7

On the business side, I want to bring up revenue growth in identification marking, where the structural investments we made over the last year are still underway at Lasit and are beginning to deliver results, and those are now being complemented by spending on distribution channels as well, so we can extend the reach of a business that is clearly showing strong growth potential. Another notable element of our 2022 results is cash generation—or rather, cash absorption during the period—which brought down our net financial position, though it remains positive and solid. We built up a substantial increase in working capital to support the fast growth. I want to emphasize the phrase built up, because this was deliberate, designed to enable smooth manufacturing performance. To raise volumes, we had to ensure every material was on hand during a period of widespread and unprecedented supply chain unreliability. That meant more purchases for rising volumes and larger in-house inventories of raw materials and components to head off the expansion and variability of lead times—the suppliers' lead times, naturally.

Andrea Cangioli

executive
#8

After that, the structural rise in inventory has at times been pushed even higher by suppliers delivering late, which prevented us from building the volumes we had planned, or by what you could call routine schedule changes on our customer's side. As an example, a supplier's delay hit us hard, despite the preventive steps taken at our subsidiary Asclepion, which had to run production at reduced rates throughout the entire summer for its best-selling system, the MeDioStar Hair Removal Diode Laser System. Another new feature of this year is the need to pay vendors more promptly and occasionally in advance through down payments. For some components, genuine competition is underway to secure the biggest possible allocations from suppliers for ourselves. We were forced to reduce payment terms so that we would have a say in that competition and could keep materials flowing steadily into our production line. Last, the close of Q3 is, seasonally, the weakest point of the year for inventories, because we hold in-house what the final quarter requires, and that quarter is consistently the strongest by far where volumes are concerned. On ratios, net working capital to revenue for the trailing 12 months stood at 25.3% at the close of 2021 and at 33.6% at the end of Q3.

Andrea Cangioli

executive
#9

Of that EUR 73 million rise in net working capital across the nine months, EUR 20 million tracks revenue growth, while 53 million is, shall we say, excess, for the reasons I just walked through. We're confident that we can bring that latter portion down. I'm equally confident that we'll still be well short of the end-2021 metrics. Naturally, the figure will depend — I mean, how much net working capital comes down in Q4 will hinge on actual results and shipments during the final months. Getting the excess portion down in Q4 would strike me as an excellent outcome. That's a goal we're aiming at, though the main objective remains making certain production activities run flawlessly. Another dominant theme of these times is inflation. Inflation in what we pay for components of every kind is hitting us, and it hits us even harder on U.S.-manufactured components because of the strong U.S. dollar, which conversely helps us on the sales side by improving margins on sales into the United States. As you can see, sales margins over the nine months were basically unchanged, with a reduction in the third quarter that in fact stemmed not from cost pressure but from the aggressive pricing policy we pursued in the industrial segment during the period so as to maximize the expansion rate of the customer base.

Andrea Cangioli

executive
#10

The effect of inflation has likewise been tempered by customers buying ahead of time, though it will ultimately hit our cost of goods sold. That is why we have begun raising prices across a number of our product lines. In some instances the change takes effect right away, in others it starts with the new year. In certain cases, instead of explicitly raising the price list, we softly achieved the goal of lifting ASPs, average selling prices, by cutting the discount headroom granted to the sales force when closing orders. Raising prices is something new for us over the last year, as we rarely applied increases to specific products. Our strategy has always revolved around continuous innovation. New price levels get set by bringing new innovative products to market, making the previously released ones obsolete, and doing so at a very high pace, drawing on the effectiveness and productivity of our R&D and engineering departments. Naturally, today's inflationary conditions mean we cannot wait for innovation cycles to finish before adjusting margins, and we had to act. Before I take you into the financial details, I would like to say a few words about the shareholders meeting coming up in December, where a new incentive stock options plan will be released that becomes exercisable in 2026.

Andrea Cangioli

executive
#11

Both our leadership team and our hard-working staff have been motivated and compensated through the currently open 2025 stock option plan, and while that plan has delivered a lot of value to the people who received awards, it has clearly worked very well for the company issuing them too. So we're putting forward a new midterm plan involving shares that will be granted essentially at market price — likely in late winter or early spring — and it should serve as a strong tool for both incentive and retention. As for its size, we're asking shareholders to approve up to 2 million shares, a pool that ought to be more than enough for the allocations we have in mind. With that introduction from me, Enrico, please go ahead with your section.

Enrico Romagnoli

executive
#12

Alright. Thank you, Andrea. I'll walk through the financial results now. As Andrea already mentioned, we enjoyed a solid third quarter on the revenue side, posting a 19.8% rise, third quarter versus third quarter. On the operating result as well, EBIT climbed 20.5% against the EUR 13.7 million recorded in the same quarter a year earlier. Across the nine months, helped by that strong quarterly showing, revenues reached EUR 484 million, 19.5% above the prior year, and that let us keep profitability at a high level, with EBIT of EUR 57.9 million, up 30%. Driven by the large sales volume, we saw a sharp gain in EBIT and in EBIT margin, with the impact on sales at 12%, above last year's 11%. Gross margin for the nine-month period came to EUR 179.5 million, roughly 19.5% higher than the EUR 150 million posted in September 2021. Gross margin on revenue stayed in line with the nine months of 2021, while showing a modest decline in the third quarter relative to the first half, much as occurred last year. Operating expenses were EUR 41.5 million, rising in absolute terms versus last year, with the impact on sales moving up from 8.4% to 8.6%.

Enrico Romagnoli

executive
#13

The higher hit to turnover comes mostly from commercial expenses, reflecting the return of international travel, trade fairs, and congresses — activities that are a significant cost, especially in the medical sector. Staff costs are rising as well, although their impact on turnover is improving. As of September, the group had 2,183 employees. EBIT, EBITDA for the first nine months was positive at EUR 67.6 million, up by 21.4% compared to the EUR 55.7 million as September 2021. Thanks to the increase in turnover and the better absorption of the operating expenses. EBITDA improved. Margin improved too. We had a decrease in depreciation and provision, and the EBIT at the end of 9 months showed positive balance of EUR 57.9 million, compared to the 44.6 million of euro at September 2021, with an EBIT margin increasing from 11% to 4%. Also the pre-tax income had an increase in 9 months, over 9 months over 27%. The net financial position at the end of September was approximately 32 million of euro. Looking to the cash flow of the 9 months in the. We had a decrease of approximately 84 million of euro from the beginning of the year, and with a reduction of 11.9 million in the third quarter.

Enrico Romagnoli

executive
#14

Even though cash profitability for the period was quite strong, it couldn't prevent a decline in net financial position — which, however, stayed positive and remained solid. Net working capital rose by EUR 74 million, driven by the requirement to supply materials so we could support scaled production volumes that are growing quickly. CapEx for the quarter came to EUR 6.3 million, and for the 9 months the total is EUR 19 million, with EUR 3 million of liquidity put into an insurance policy and booked in financial fixed asset to reflect its multi-year nature. Group companies have invested in this instrument in past years as well, and at September 2022 the total value of this type of investment was over EUR 21 million. During the nine months, the group paid a dividend of EUR 17.2 million, equal to 20 euro cents per share. Looking at the business breakdown, we saw growth. That growth was significant across every market segment in which the group operates. Double-digit results were posted both in the medical sector, which grew by 22.7%, and in the industrial application sector, which showed a 15.7% increase. Aesthetics, the most important segment, ended the period with revenues of EUR 167 million versus EUR 140.5 million in September 2021, up almost 20% with a 61% share on the medical sector.

Enrico Romagnoli

executive
#15

One share slipped a bit because the other segment grew even faster — it had taken the hardest hit during the worst stretches of the pandemic and has since recovered. Surgery posted the strongest gain, though: 35.2%, with a result of EUR 43.8 million versus EUR 32.4 million in the same period last year, also beating the record levels set in 2019. That target was met in therapy as well, where turnover rose 20.7% to EUR 11.6 million, against EUR 9.6 million in the same period of 2021. In aesthetics, sales were excellent across all the main application segments — hair removal of tattoos and pigmented lesions, body treatments, and skin rejuvenation. Revenue and after-sales service climbed 25.9% and now account for close to 20% of the medical sector's turnover, rising sharply thanks above all to sales of optical fibers for urology surgical applications. The industrial sector posted growth of more than 15%. That is a very positive result given the negative condition of the Chinese market, which is the group's main market in the sector. Revenue came to 215.8 million EUR, compared with 184.8 million EUR in 2021. Turnover was driven by the laser cutting segment, which recorded revenues of 108.5 million EUR versus 156 million EUR in the nine months of 2021, an increase of 16%.

Enrico Romagnoli

executive
#16

Laser cutting showed a really strong sales trend in Italy and across Europe, whereas in China results came in below forecast because of the constraints caused by the fresh round of lockdowns imposed on Chinese territory and because the economic picture remains uncertain. In Italy, Cutlite Penta posted a very positive sales trend, with an extraordinary 62% increase in revenues. Cutlite do Brasil also did very well, with 10% growth over the nine months in local currency. The marking segment picked up pace in the quarter and delivered 15% revenue growth, while the laser sources sector stays flat. After-sales service sales rose 18%, consistent with the larger installed base. Turning to revenue by area, we grew in every geographical region except the rest of the world industrial sector, given the situation in China. In China, during the period, there was a 17% decline in local currency, and 9% in Europe. Conversely, we have a very brilliant result in industrial, thanks to Cutlite Penta's very good performance, mainly in Italy and the rest of Europe. In medical, we saw a strongly positive trend in all areas, and absent the production issues tied to the supply chain, growth in Italy would have largely hit double digit.

Enrico Romagnoli

executive
#17

To wrap up, where demand, our order backlog, and manufacturing capability stand right now gives us reason to anticipate a very favorable close to the year, consistent with the outstanding performance posted thus far in 2022. The company reaffirmed the guidance it previously provided, calling for yearly consolidated revenues above EUR 660 million and a net EBIT margin matching what we delivered across the first nine months of the year. That concludes the presentation, and we're now ready to take your questions.

Andrea Cangioli

executive
#18

Let me add one remark at this point. What I mean is that we are reaffirming the guidance that was issued in September, and we will surpass the EUR 660 million annual revenue threshold, and we expect to hold through the end of the year the record EBIT margin level achieved so far in 2022. There is scope for a fairly substantial beat of the minimum EUR 660 million revenue, particularly if the Chinese market shows just a bit more vitality than it did over the last months. While we have strong confidence in an excellent Q4 performance from the medical sector and from the other industrial businesses, meaning cutting outside of China, but also marking. Also, because the leverage effect seasonally drives EBIT margins higher in the fourth quarter, our profitability guidance can likewise be viewed as prudent. This takes into account possible soft sales volume in China owing to the inability to recognize revenue from installed systems because of lockdown limitation and also some inflationary impact on margins. I wanted to offer this comment on our guidance as well before we open the session to the Q&A. Thank you.

Bianca Fersini-Mastelloni

executive
#19

We're opening the Q&A portion now. To ask a question, please sign up through Bianca Fersini Mastelloni's chat, and the floor will go to you in the order your request came in. Andrea, we've already got questions coming in. Up first is Giovanni Selvetti from Berenberg. Please go ahead, Giovanni.

Giovanni Selvetti

analyst
#20

Hello, Andrea. Hello, Enrico. Hi there. Thank you for taking my question. I have several. My first one concerns FX. Could you please provide the impact of FX on top-line growth, especially in aesthetics in China? I just want an idea of the volume trajectory — how much would volumes decline in Q3 without the positive effect of the renminbi? My second question is about prices, on the press release, and earlier you mentioned that for the first time in recent history you are raising prices to offset the impact of cost inflation. Could you please elaborate a bit more on this: what is the size of this increase, and is it spread between the two divisions or does it affect only the medical division? I am not sure I understood correctly earlier, but you said the reduced margin in Q3 was also mainly due to some pricing applied in the industrial division, meaning that you lowered prices in the industrial division to expand the customer base. My third question is on Accure. When should we expect the FDA clearance for this product, and how will it differ from the recently launched AviClear from Cutera?

Giovanni Selvetti

analyst
#21

The final question from me concerns supply chain constraints. Asclepion has, I think, been dealing with these issues for a number of quarters at this point, so I wanted to ask which particular components Asclepion relies on are unavailable and which the group's other companies are unable to supply. That's all from me.

Andrea Cangioli

executive
#22

Giovanni, thanks for the question, and thanks for joining us on this call. On a global basis, the foreign exchange impact on the top line came to 3.7% over the nine months and 4.2%, so a bit higher across the three months. When we look at the renminbi portion alone, the effect was roughly 9.3%, for both the nine months and the quarter. To be precise, it's 9.3% across the nine months and 9.5% over the three months. I'd like to emphasize that there is, in the end, an even larger swinging foreign exchange effect, and that is the real, the Brazilian currency, which naturally carries less weight, but it is significant from a certain standpoint, which I'd put at around 14%, for both the quarter and the nine months in terms of foreign exchange effect. As for the real, we enjoy a pure advantage there, since the Brazilian subsidiary buys its goods in euros and sells them locally in real. So the strengthening of the real means, for us, an increase in margins. That does not apply to the renminbi, where we are simply converting in full the financials of our Chinese subsidiaries without gaining a real advantage in terms of trading. As for the U.S.

Andrea Cangioli

executive
#23

When it comes to dollars, at the group level we actually hold a margin advantage overall, because ultimately the revenue we record in dollars exceeds the costs we incur in dollars. That said, although our U.S. dollar revenue is climbing rapidly thanks to how well sales to the U.S. subsidiaries are doing, dollar-denominated purchases are climbing too, so the margin impact we see amounts to less than half of the impact on the top line. Pricing — the pricing question. Yes, you caught what I said regarding aggressive pricing in the industrial business. That has nothing to do with the inflation effect. Put simply, our margins are low because we set low prices, not because setting low prices was a strategic choice aimed at expanding our footprint during this period. Even so, in both that area and the medical area, we are putting through price increases that going forward will land at roughly 10% for the medical business, and likely slightly under that for the industrial laser system. During my presentation, what I noted was that instead of raising list prices, in some situations we simply refrain from granting discounts, since in certain markets a 10%, 15% discount off the list price is fairly standard practice when a sale is closed.

Andrea Cangioli

executive
#24

By capping the maximum discounts at, say, 5% or a 3% threshold, we're actually raising average selling prices. Accure is expected to get FDA clearance by the end of the year. That's the most recent update from our subsidiary, and this news has been delayed several times. That's what we know today, and it would come as a surprise if we didn't obtain FDA clearance before the year is out. Our product is entirely unlike AviClear, which has enjoyed tremendous success. It has been a great disappointment to us that Cutera obtained FDA clearance ahead of us. That's how things played out. Unfortunately, as I mentioned, our partners weren't as quick as we might have hoped in capitalizing on their first-mover advantage, since we were by far the earliest mover in this space and were beaten to FDA clearance by Cutera. Our product is certainly more complete and is expected to be considerably more effective, given the technology and the narrowness of the emission, which sits precisely at the most effective wavelength and concentrates a very high energy density.

Andrea Cangioli

executive
#25

We anticipate that our unit will be more effective. The flip side of units being more effective is that the unit also costs more, and so it would be, it would cost more, and it will be up to our partners and to the funders of the business to find the right approach in order to maximize sales also in presence of a higher cost of goods sold. Asclepion. You're right. Why is Asclepion the only company which is behind, which had problems which we could not solve in a short time? It's a good question. The answer stays also in the fact that we are talking of a medical product. We are talking of a very special medical product. We are talking of a product which is by far the best in kind in the world, and therefore, in order to obtain this kind of performance, has very specific components and very specific subassemblies that are not easily replaced in a short time, especially now. Give you an example. They had a traditional manufacturing of a component which is part of one of the key control units of the laser made by a local manufacturer in Germany. We tried to convert production in Italy, but also the manufacturing facilities we found in Italy gave us delivery for the first batches after nine months.

Andrea Cangioli

executive
#26

You should understand that the manufacturing environment we're competing in has become very sluggish to respond. We took every step available to us to get past these difficulties. The challenge with our products is that they consist of hundreds of components, and any single component can turn critical when it's absent, in a kind of chain reaction where a $5 part could halt output of $100,000 or EUR 100,000 units. The good news is that, at least regarding the units for the components that had slowed production over recent months, the issues are resolved. Naturally, after you fix a problem on one unit, there's always a chance that other units will slow the process down. We're expecting a positive close to Q4 for Asclepion and that they'll be able to recover what was lost during the first nine months by materially improving their manufacturing pace across the last two months, the last three months. I hope that answers the question.

Giovanni Selvetti

analyst
#27

Yeah. No.

Andrea Cangioli

executive
#28

Maybe every one of your questions, Giovanni Selvetti.

Giovanni Selvetti

analyst
#29

I don’t want to use up other people’s time. Maybe I could take one more, but I’ll simply leave space so others can ask.

Andrea Cangioli

executive
#30

Alright, perhaps you could put that question to some of the others.

Giovanni Selvetti

analyst
#31

Sure, sure, wrapping up at the end works for me. Thanks.

Andrea Cangioli

executive
#32

Glad to help.

Bianca Fersini-Mastelloni

executive
#33

Alright. Andrea, Francois Robillard from Intermonte has one more question for us.

François Robillard

analyst
#34

Hello, everyone. Good afternoon, and thanks for taking my question. My first one concerns your guidance for the year. As you yourself noted, both the EUR 660 million base for your top line and the indication for the EBIT margin may leave a fair amount of room to be beaten in the fourth quarter. What factors led you to refrain from upgrading those statements? Do you perceive any risks that things could deteriorate in the fourth quarter? That was my first question. My second question concerns China. Could you give us an update on how activities have been progressing during the first weeks of the fourth quarter, and on your level of confidence regarding a potential recovery there, or an improvement of the situation there? Another question was more on the cash flow side. If I understood correctly, another cash burn from working capital in the fourth quarter might not be out of the question. Would you consider at some point moving into a net debt position in order to keep production lines running? And if so, to what extent? The next question to this one, I guess, would be what your expectations are for working capital evolution potentially in the fourth quarter, and how much of it is tied to your activity growth in China?

François Robillard

analyst
#35

Possibly just one last question here — one of your rivals has pointed to fairly strong results for a women's health offering, I believe the name is EmpowerRF RF. Could you speak to that? Is some market share slipping away from you? How does this competitor product's success affect you? Thanks a lot.

Andrea Cangioli

executive
#36

Thank you, Francois. On guidance: we chose not to revise it, since any change would likely have been marginal, and as I said, certain risk factors exist. So we kept guidance as it was, and we noted that we feel confident about exceeding it, although the situation in China in particular warranted some caution for the reasons I gave earlier. In China specifically, conditions are not progressing much more quickly than they did last month. We should, however, be in a position to complete a substantial number of installations that sit in inventory on one hand and are not generating sales on the other. Because revenue recognition in China requires explicit customer approval of the installation, and that is not always straightforward — particularly for large installations, and particularly in regions where lockdowns prevent salespeople from moving about freely. What I mean is that this remains subject to a certain amount of uncertainty. Regarding the cash position, I apologize if my earlier remarks were in any way misleading. I stated that we anticipate the ratio of net working capital to sales will decline in the fourth quarter. Naturally, we also anticipate that sales volume for the last 12 months will rise, but we likewise anticipate a decrease in the absolute value of net working capital.

Andrea Cangioli

executive
#37

Here's what we're expecting. We don't anticipate having to push the company into a debt position to fund the growth, but we do count on being able to reverse the net working capital cycle beginning with this Q4. Regarding the RF products in women's health, the problem comes down to the target market. There are companies — if you're referring to whether it's InMode's product — they aren't aiming at the same market as we are. It's a gynecologic device that they sell to gynecologists, but it's a device they sell more or less to the entire market of derms and practitioners. It's a product we can't fight against, because our devices lack the clearances that would let us aggressively market against them. I believe they themselves don't have those clearances, but even so, they can market it right now, and they're able to achieve solid success. As I've said several times, we're not happy with where things stand with MonaLisa Touch, our gynecologic vaginal atrophy device, which was created by the 2017 FDA intervention on the matter. Mainly because of that specific intervention — or also because of it — we're not able to market freely in the U.S.

Andrea Cangioli

executive
#38

For our device, the sole path to restoring a robust marketing effort is securing a de novo or fresh FDA clearance, and that requires a very substantial investment. For quite a while now, we've been in discussions with our partner Cynosure about how much investment would be needed to obtain that clearance. This would be a project costing multiple millions and running for a minimum of 4 years. We have not reached an agreement with Cynosure. At present, the project is, so to speak, on hold. If we can, we will need to find other partners, since El.En. cannot carry such a project on its own — not because it lacks the financial capability to do so, but because El.En. believes it must team up with a suitable partner to ensure that distribution succeeds once clearance is secured in line with the specifications we are pursuing. The bottom line is that right now, in the MonaLisa Touch market segment, we are seeing a solid sales increase, although the volume stands at roughly 1/3 of the peak volumes we enjoyed in 2016 and 2017. At this moment, the project is being followed in some fashion, yet we still lack the green light to proceed with the large products project that would unlock MonaLisa Touch sales in the U.S.

Andrea Cangioli

executive
#39

Across a span of roughly 4 to 5 years. I trust that addresses what you asked. Many thanks.

Bianca Fersini-Mastelloni

executive
#40

Next up, we’ve got Paolo Cipriano calling in from TP ICAP. Paolo, the floor is yours — please go ahead.

Paolo Cipriano

analyst
#41

Good afternoon. I’d like to ask about inflation. Would you be able to expand a little further on cost inflation — how that trend is shaping up during the second half of the year, and also with respect to which cost components?

Andrea Cangioli

executive
#42

All right. So what we're seeing is that inflation is generally pushing up the cost of components. Essentially, when we place orders, they come with price increases of about 10% across all our materials. Naturally, for critical materials where we place bigger orders, volumes may have led to a more favorable trend. We also place larger orders for materials whose inflationary cost pressure is even higher, because manufacturers aren't able to raise their volumes. We're requesting volume increases so we can support the revenue growth we've projected. On average, I'd say we're paying roughly 10% more on all our purchases. Then there's a second kind of inflation, which is energy inflation. That one is embedded in the purchasing costs I just described, and it adds to our general expenses—particularly at the Italian companies, where both the electricity bill and, where applicable, the gas bill for the gas we use for heating are climbing substantially. The thing is, this year, with such fast growth at most of our major Italian facilities—I'm referring to Quanta System, El.En., and CutlitePenta, all of which are growing at strong double-digit rates—the rise in general expenses has been significant, but the leverage from higher revenues has meant we haven't felt the effect on our financial result of the cost increases, which in some cases have been extremely significant, with energy costs within each company's general expenses tripling or even more.

Andrea Bonfà

analyst
#43

All right, thanks.

Bianca Fersini-Mastelloni

executive
#44

We’ll now take a question from Andrea Bonfà at Banca Akros. Andrea, please go ahead.

Andrea Bonfà

analyst
#45

Good afternoon, everyone. So my question is, once again, whether you could go into a bit more detail on the component shortage, Andrea — in the sense that the example you gave earlier was definitely clear. I was wondering whether this scarcity is, let's say, a byproduct of the strong CapEx cycle worldwide, or where it actually comes from. Because, I mean, okay, we had the pandemic, and we know about the fallout effects. Just to try to understand who your competitors are for these components, if that's possible. Then, if you could quickly recap, let's say, the new product clearances and the geographies that will contribute to next year's growth, also China, if that is your opinion. Then, I'm still confused about the price hike. Did I understand correctly that you are planning to raise prices by 10% starting from the Q4, or is it — maybe I misunderstood it? Thank you.

Andrea Cangioli

executive
#46

Alright, Laura — apologies for beginning with the final question, the one about price increases. Yes, I did state that we're raising prices, though not across every one of our companies, only in a number of businesses, and that the rate of increase is roughly 10%. I also mentioned that in some cases we haven't raised prices explicitly; instead, we lift average selling prices implicitly by cutting back on the discounts we allow. The target figure, yes, is approximately 10%. That's what we're aiming for. What we're already achieving, at least regarding new orders booked in 2022 for delivery during 2023, depends on certain circumstances. On the subject of new products and geographic clearances: China is a place where we don't anticipate any specific product receiving clearance. Naturally, as you're aware, clearances affect medical systems only. Selling industrial systems — our primary market in China — requires no clearance at all. As for medical laser systems, we are pursuing clearance for a new body sculpting device to be sold in the United States; it's the successor to the existing unit known as PHYSIQ, and it will deliver a different, more effective emission along with broader market clearance so that our distribution networks can market it very effectively.

Andrea Cangioli

executive
#47

We also anticipate solid revenue growth in that same market from Onda, which secured a clearance under the name TiteK2, and it will serve as a distributor under the name Sculpt through one of our distribution partners, Sentient, which is handling distribution of the product in the United States. We're expecting a very interesting result from them. We also expect a new CO2 device to be ready for sale in the United States early in 2023. That device goes by the name Helix. Clearance should come momentarily, within the end of the year, so that sales can begin already from Q1 2023. Of course, you should know that a great deal of regulatory activity over the last months has been slowed down by the missing publication and approval of the common specification underlying the European Commission's new MDR directive, concerning especially medical aesthetic devices. The regulation has finally been approved and is awaiting the final signature by the European Commission. Without this regulation, clearing new products is basically not possible, because the rules under which new products can be cleared are unknown. For this reason, we have several products in the pipeline for hair removal, for pigmented lesion treatments, for body shaping, for skin resurfacing, for tattoo removal.

Andrea Cangioli

executive
#48

Compared with how things used to work — where securing the CE mark was the initial step toward distributing a product — at this stage, FDA clearance is somewhat easier to obtain. Because even though that process is burdensome and complicated, it follows established, known rules, so getting an FDA clearance is simpler than getting a CE mark. Even so, we're quite optimistic that once this regulation is finally loosened up, we'll manage to build a substantial number of units in the certification pipeline and we'll be able to bring new products into our sales force. I should keep in mind that, in any case, after you secure the CE mark to sell in the CE countries, it then takes some time before the product is released for sale in other countries around the world. So this year and next year, we anticipate clearances following for a range of countries and a range of devices. Incidentally, we've just received release in Korea for certain devices, and after several years during which the Korean market hasn't been so strong for us, we expect to be able to grow sales, particularly in the body space, in the body contouring devices.

Andrea Cangioli

executive
#49

Turning to your question about component scarcity and the latter portion of what you asked—namely, who the competitors are—the primary problems we encountered involved high voltage components for our power supplies. Our systems require high voltage power supplies and very sophisticated components capable of handling high powers at high voltages. The segments dealing with high voltages and high powers are the electric vehicle segment and the solar panel management market. Both of those markets are expanding very rapidly, and you can appreciate that even if they aren't directly competing with us for specific components, they are competing with us for the same providers of high power components. That, I believe, is why we generally ran into component shortages in this particular area. This is also the area in which Asclepion devices have had their manufacturing pace slowed down. What I mean is that the subassemblers unable to deliver certain components on time are large companies that had anyway been slowed down by the slowdown in manufacturing of those components, or at least by the slowdown in manufacturing of those components relative to the very rapid increase in demand that these components have experienced.

Andrea Bonfà

analyst
#50

Thanks, Andrea. If I could just touch on Europe’s new regulatory framework — my assumption is that the whole industry is being held back by it. It’s not something that affects only you, I mean.

Andrea Cangioli

executive
#51

Sure. This is a major problem across the entire industry. If you look at the papers or follow the news, the industry news, the whole sector is in serious upheaval owing to this extraordinary delay in getting regulations delivered.

Andrea Bonfà

analyst
#52

I appreciate that.

Bianca Fersini-Mastelloni

executive
#53

I'll take another question from Giovanni Selvetti at Berenberg. Go ahead, Giovanni.

Giovanni Selvetti

analyst
#54

Hello there. So, yes, I merely wanted to get an update regarding how things stand with Asclepion. What I asked was whether the revenue shortfall tied to Asclepion was offset in some way by the group's other products that are sold?

Andrea Cangioli

executive
#55

Yes, when you look at the group as a whole in terms of volume, certainly—since we're up 20%, or in the aesthetics business without Asclepion's support. To be specific, the systems sold to Asclepion's own customers relied on Asclepion technology, and generally we can't fill the gap with other group products, because that technology, as I explained, is an area where Asclepion excels, and Cynosure makes a product that is unique worldwide, yet also unique inside the group. No other companies of ours could supply a product for that application using the same technology. In certain circumstances, in certain cases, we managed to prevent the loss of particular customers by offering other group-manufactured products built on different technologies. The difference here is a big one. Instead of giving an end user a semiconductor hair removal laser, we'd offer an Alexandrite hair removal laser, which, I mean, under certain profiles might even be viewed as more effective, but it is an entirely different product. In certain cases, swapping one system for the other is impossible, since customers specifically want that technology. Incidentally, let me remind you that being able to meet the needs of customers who want different technologies and a different approach has been one of the group's competitive advantages—with its multi R&D center, multi manufacturing site, and multi distribution network approach, it can capillarily cover all needs with every requested technology.

Andrea Cangioli

executive
#56

Let me give you an example that's simple, really simple to grasp. Essentially, you could think of the diode hair removal laser as an Apple technology iPhone—an iPhone technology—whereas the alexandrite laser is more like an Android device. These are two entirely separate worlds, and customers prefer to stay within their own world, yet we serve both through our group: Android and Apple, alexandrite and diode lasers. Our penetration is the best, but when someone wants an Android, you can't hand them an Apple instead, and the same holds in reverse.

Giovanni Selvetti

analyst
#57

All right, thanks. And if I could just come back once more — is that new investment in Samarate for Quanta meant to boost output of surgical lasers, or of aesthetic lasers?

Andrea Cangioli

executive
#58

The purpose of these is to increase capacity at both segments. We expect quite rapid growth in each of those segments. Naturally, if the Accure line comes online, aesthetics would face the greatest pressure. What we've done in Samarate is essentially this: we're now renovating the second building. Anyone who has joined our company visit in Samarate has seen one building. We purchased the building next door, and it's currently being refurbished so it can serve for offices as well as production, expanding all the lines, both surgical and medical. One key point to note, of course, is that we will relocate the clean rooms required for making the optical fibers. Those clean rooms sat in the old buildings and had started to block expansion of certain production stages we need to grow inside the old building. We're relocating and enlarging the clean rooms to raise optical fiber capacity and also to free up space in the older building, which will then be usable for medical, surgical, and aesthetic output.

Bianca Fersini-Mastelloni

executive
#59

Andrea —

Giovanni Selvetti

analyst
#60

Thanks. Thanks a lot, Andrea.

Bianca Fersini-Mastelloni

executive
#61

Apologies. We have another question coming from Emmanuel de Figueiredo at LBV. Please proceed, Emmanuel. Thank you.

Emmanuel de Figueiredo

analyst
#62

Hi there. In last night's press release, I noticed the mention of a potential IPO in China. My question is really this: which parameters ought we to be watching for, and what about timing? Is the Chinese market recovering first what you're waiting on? Or are you holding out for Chinese stock multiples to recover? Or perhaps you're waiting on some kind of regulatory green light? Anything you can share regarding the considerations that would determine whether you actually go ahead and make this happen?

Andrea Cangioli

executive
#63

Yes, that plan exists. We're taking every step required right now to carry it out, and that includes bringing new investors into the shareholder base. Naturally, every point you raised is accurate. The key issue is that the company will need a particular scale and a particular level of profitability before we can file for the demand. When we're able to file will, naturally, hinge on how the company performs financially. Once we judge it appropriate — once the right moment to file arrives — the filing process, in China, takes a very long time. Handling by the CSRC is expected to take around 12 months. Any filing we undertake would rest on the assumption and the conviction that over the coming months the Chinese economy would recover step by step. Those are the constraints and the factors we're weighing as we decide whether to proceed and move forward with this project.

Emmanuel de Figueiredo

analyst
#64

All right, just a brief follow-up. Those two — I believe I saw them in the release — two Chinese private equity firms. Is that something probably going to happen within the next 6 months or 12 months, or what's the timeline on it?

Andrea Cangioli

executive
#65

That has already taken place.

Emmanuel de Figueiredo

analyst
#66

Oh, that's already happened?

Andrea Cangioli

executive
#67

That's already done — I mean, it's already been completed. We finalized it during October. This is a situation where they're already part of our shareholder base.

Emmanuel de Figueiredo

analyst
#68

Right, the figures haven't come out yet, have they? That hasn't been released so far, or has it?

Andrea Cangioli

executive
#69

Yes, we did.

Emmanuel de Figueiredo

analyst
#70

Mm-hmm.

Andrea Cangioli

executive
#71

Regarding the valuation of the business unit led by Penta Laser Zhejiang — that covers the three Chinese companies, Penta Laser Zhejiang in Wenzhou, Penta-Chutian Laser (Wuhan) Co., Ltd. in Wuhan, and Penta Laser (Shandong) Co., Ltd. in Linyi, along with the Italian company CutlitePenta — the overall valuation, the pre-money valuation, stood at CNY 12 billion.

Emmanuel de Figueiredo

analyst
#72

Alright, thanks.

Andrea Cangioli

executive
#73

That comes to about EUR 170 million, more or less. The valuation worked out to approximately 12 times 2021's adjusted EBITDA. It's adjusted since it left out some international accounting standard adjustments that were booked in 2021 within the Chinese financials, and those arose from the company's conversion into a corporation, which happened in February.

Emmanuel de Figueiredo

analyst
#74

Thanks.

Bianca Fersini-Mastelloni

executive
#75

I’d like to check whether there are any additional questions from the floor. Any more questions? Andrea, there are no further questions on our list, and if no one else in the room has a question, let’s bring this conference to a close. Thank you for joining us, and we look forward to having all of you with us at the next occasion. Good afternoon, everyone.

Paolo Cipriano

analyst
#76

Take care, Enrico.

Bianca Fersini-Mastelloni

executive
#77

Bye. Bye.

Andrea Cangioli

executive
#78

Bye. Thanks a lot.

Paolo Cipriano

analyst
#79

Take care, everybody.

Bianca Fersini-Mastelloni

executive
#80

Bye. Thanks a lot. Bye.

Paolo Cipriano

analyst
#81

Bye. Thanks. Ciao, thank you.

Bianca Fersini-Mastelloni

executive
#82

Take care.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.